We present our experience planning and launching a multinational, NIH/NINDS funded study of thymectomy in myasthenia gravis. We highlight the additional steps required for international sites and analyze and contrast the time investment required to bring U.S. and non-U.S. sites into full regulatory compliance. Results show the mean time for non-U.S. centers to achieve regulatory approval was significantly longer (mean 13.4 ± 0.96 months) than for U.S. sites (9.67 ± 0.74 months; p = 0.0175, t-test). The delay for non-U.S. sites was mainly attributable to Federalwide Assurance certification and State Department clearance.
Background
This manuscript describes our experience in the planning and launching of an international, multicenter, clinical trial funded by the National Institute of Neurological Diseases and Stroke (NINDS) of the National Institutes of Health (NIH) to study the role of thymectomy in myasthenia gravis (MG). By summarizing our experience, we hope to assist other investigators who are organizing clinical trials that will involve international collaboration.
MG is a chronic autoimmune neuromuscular disease that fulfills established criteria as a rare disease. Prevalence rates range from 0.5 to 20.4 per 100,000 (Phillips, 2003) . No regions of particularly high or low incidence or prevalence have been identified, but most studies have focused predominantly on Caucasian populations of western European descent. Studies of South African, African American, and Asian populations suggest that there may be differences in racial susceptibility (Chiu et al., 1987; Phillips et al., 1992; Wong et al., 1992; Heckmann et al., 2007) . Clinical investigation of MG is further complicated by the presence of disease subgroups based on the presence of antibodies against the acetylcholine receptor, muscle-specific kinase or absence of detectable auto-antibodies. Age of onset, presence of thymoma, and the presence of pure ocular versus generalized disease appear to define other patient subgroups (Compston et al., 1980) .
The thymectomy trial for non-thymomatous myasthenia gravis patients receiving prednisone (MGTX) is an NINDS cooperative multinational, multicenter, two-arm trial that is currently enrolling patients. The study aims to determine if extended transsternal thymectomy plus prednisone compared to prednisone alone results in a greater improvement in MG Journal of Neuroimmunology 201-202 (2008) 80 -84 www.elsevier.com/locate/jneuroim
